News | Heart Valve Technology | February 04, 2021

Bicuspid Aortic TAVR May Create Huge Market For Transcatheter Valves

Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.

February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the patients with bicuspid valve valves, but recent studies may soon open the door to wider use of TAVR in this population.

“Physicians have previously been cautious about using TAVR in patients with bicuspid valve stenosis due to a number of factors," explained Ashley Young, senior medical devices analyst at GlobalData healthcare market research. "Perhaps most importantly, the long-term durability of TAVR valves has yet to be thoroughly proven in a robust clinical trial setting. This is of utmost importance to patients with bicuspid aortic valve anatomy, who typically present with stenosis at a younger age and depend on long-term durability of replacement valves.”

GlobalData predicts that up to 53% of adult patients with diagnosed severe aortic stenosis have bicuspid valve anatomy, representing a huge potential for market expansion if TAVR devices are able to extend into this population. With the recent update to the precautionary labels of both the Edwards Lifesciences and Medtronic TAVR valves, this seems like a possibility for the near future.

“Once physicians become more comfortable with the recent clinical data supporting the use of TAVR devices in patients with bicuspid valve anatomy, GlobalData predicts that TAVR usage in this population will grow at a double-digit CAGR, mimicking the success of the procedure in the tricuspid valve population,” Young said.

A late-breaking study at the 2020 American College of Cardiology (ACC) meeting was the first to prospectively examine TAVR’s safety for treating severe aortic stenosis in relatively young, healthy patients—in whom open-heart surgery would pose a low risk—who have a bicuspid valve. It also is one of the first studies involving such patients in which doctors used a newer self-expanding artificial valve. The study prospectively tracked 150 patients who underwent TAVR at 25 medical centers in the U.S. and found TAVR is a safe alternative to surgery in bicuspid patients.

“This clearly has clinical implications with patients with bicuspid valves who want TAVR," said Basel Ramlawi, M.D., cardiothoracic surgeon at Lankenau Medical Center and the study’s co-principal investigator. "TAVR with a self-expanding prosthesis is a very viable and safe procedure in low-risk bicuspid patients and achieved excellent early results. Though additional follow-up is necessary to determine long-term outcomes, early results suggest this procedure can be performed successfully in low-risk individuals with a good outcome.” 

Aortic stenosis is one of the most common valvular heart diseases, with the moderate to severe form of the disease affecting nearly 2 million people in the U.S. alone. While the majority of people have tricuspid aortic valve anatomy with three valve leaflets, a portion of the population has bicuspid aortic valve anatomy with only two leaflets. This variation of anatomy only affects between 2-5 percent of people, but the anatomy makes makes it more likely to develop calcification of the valve that leads to aortic stenosis. 

GlobalData said the use of TAVR is rising at a compound annual growth rate (CAGR) of 1% in most countries.

For more information: www.globaldata.com

 

Related Bicuspid TAVR Content:

VIDEO: TAVR Performs Well in Bicuspid Aortic Valve Patients — interview with Basel Ramlawi, M.D.

Canada Clears Medtronic Evolut TAVR for Both Bicuspid Valves and for All Low Risk Patients

VIDEO: Explaining Bicupid Aortic Valves

TAVR Shows Favorable Safety in Patients with Bicuspid Valve

TAVR Expected to See Rapid Growth in Next 5 years

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now